Results 31 to 40 of about 4,349 (172)

Impairment by Hypoxia or Hypoxia/Reoxygenation of Nitric Oxide–Mediated Relaxation in Isolated Monkey Coronary Artery: the Role of Intracellular Superoxide

open access: yesJournal of Pharmacological Sciences, 2011
.: To investigate the effect of hypoxia or hypoxia/reoxygenation on vascular smooth muscle function, mechanical response of monkey coronary artery without endothelium was studied under normoxia, hypoxia, and hypoxia/reoxygenation.
Masashi Tawa   +6 more
doaj   +1 more source

Reducing Anticholinergic Burden in Hospitalised Older Adults: Analysis From the INFAR Study

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 138, Issue 1, January 2026.
ABSTRACT This study aimed to evaluate the effectiveness of pharmacist‐led medication reviews in reducing the anticholinergic burden of hospitalised patients with cardiovascular diseases (CVDs), to identify which anticholinergic medications were most frequently prescribed or discontinued during hospitalisation and to investigate factors associated with ...
Romana Santos Gama   +4 more
wiley   +1 more source

Coronary Spasm Due to Pulsed Field Ablation: A State‐of‐the‐Art Review

open access: yesPacing and Clinical Electrophysiology, Volume 49, Issue 1, Page 43-51, January 2026.
ABSTRACT With the ever‐growing population of patients undergoing cardiac ablation with pulsed electric fields, there is a need to understand secondary effects from the therapy. Coronary artery spasm is one such effect that has recently emerged as the subject of further investigation in electrophysiology literature.
David A. Ramirez   +3 more
wiley   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1463-1476, December 2025.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu   +21 more
wiley   +1 more source

Comparison of short head-up tilt test with conventional protocol after omission of nonmedicated phase in children and young adults

open access: yesAdvanced Biomedical Research, 2016
Background: Syncope is an important and common clinical condition, and the neurally mediated syncope is the most frequent type of syncope. Tilt testing is considered as a first-line diagnostic test.
Bahar Dehghan, Mohammad Reza Sabri
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1430-1436, December 2025.
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with ...
Michael T. Eadon   +18 more
wiley   +1 more source

Possibilities of nicorandil for coronary insufficiency correction in patients with ischemic heart disease and diabetes mellitus type 2

open access: yesМедицинский совет, 2019
Cardiovascular complications of type 2 diabetes mellitus (T2DM) are now a global health problem, due to their main cause of mortality of these patients. Ischemic heart disease (IHD) among all cardiovascular diseases occupies a leading position.
Zh. M. Sizova   +2 more
doaj   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

open access: yesEuropean Journal of Heart Failure, Volume 27, Issue 12, Page 2671-2690, December 2025.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin   +16 more
wiley   +1 more source

Medical therapy following hospitalization for heart failure with reduced ejection fraction and association with discharge to long-term care: a cross-sectional analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population

open access: yesBMC Cardiovascular Disorders, 2017
Background Less intensive treatment for heart failure with reduced ejection fraction (HFrEF) may be appropriate for patients in long-term care settings because of limited life expectancy, frailty, comorbidities, and emphasis on quality of life.
Emily B. Levitan   +11 more
doaj   +1 more source

Analysis of outcomes in patients with HeartMate 3 with and without right ventricular assist device support

open access: yesESC Heart Failure, Volume 12, Issue 5, Page 3306-3319, October 2025.
Temporary RVAD support following HM3 LVAD is associated with high morbidity and mortality. Temporary RVAD support occurs most frequently in INTERMACS 1 or 2 patients and those who require pre‐operative VA‐ECMO. In addition to higher post‐operative mortality, a significantly higher risk of both dialysis and stroke at 1 year post‐implant was observed in ...
Vinh Q. Chau   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy